LC
SPRY icon

Lindbrook Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Lindbrook Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$9.54K Sell
758
-47
-6% -$565 ﹤0.01% 1675
2024
Q4 		$8.49K Sell
805
-50
-6% -$700 ﹤0.01% 1734
2024
Q3 		$12.4K Sell
855
-6
-0.7% -$71 ﹤0.01% 1557
2024
Q2 		$7.33K Buy
861
+161
+23% +$1.43K ﹤0.01% 1806
2024
Q1 		$7.15K Hold
700
– – ﹤0.01% 1738
2023
Q4 		$3.84K Buy
700
+491
+235% +$2.15K ﹤0.01% 2024
2023
Q3 		$790 Buy
+209
New +$1.37K ﹤0.01% 2420

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Lindbrook Capital's SPRY Position: Q1 2025 in Review

Lindbrook Capital reduced its ARS Pharmaceuticals (SPRY) stake by 5.8% in Q1 2025, selling an estimated $565 and leaving 758 shares worth $9.54K. The position accounts for ﹤0.01% of the portfolio, ranked #1675.

Lindbrook Capital first reported a position in SPRY in Q3 2023 and has held it in 7 quarters since. The position peaked at $12.4K in Q3 2024. 184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

  • Lindbrook Capital held 758 shares of ARS Pharmaceuticals worth $9.54K as of Q1 2025.
  • Lindbrook Capital sold 47 ARS Pharmaceuticals shares in Q1 2025, an estimated $565.
  • ARS Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1675 holding.
  • Lindbrook Capital first reported a position in ARS Pharmaceuticals in Q3 2023 and has held it in 7 quarters since.
  • Lindbrook Capital's ARS Pharmaceuticals position peaked at $12.4K in Q3 2024.
  • 184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.